Arrowhead Pharmaceuticals, Inc. (ARWR)
ARWR Stock Price Chart
Explore Arrowhead Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze ARWR price movements and trends.
ARWR Company Profile
Discover essential business fundamentals and corporate details for Arrowhead Pharmaceuticals, Inc. (ARWR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Dec 1993
Employees
609.00
Website
https://arrowheadpharma.comCEO
Christopher R. Anzalone
Description
Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.
ARWR Financial Timeline
Browse a chronological timeline of Arrowhead Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$1.19, while revenue estimate is $47.84m.
Earnings released on 7 May 2026
EPS came in at -$0.93 surpassing the estimated -$1.09 by +14.68%, while revenue for the quarter reached $73.74m , missing expectations by -0.14%.
Earnings released on 5 Feb 2026
EPS came in at $0.22 falling short of the estimated $0.60 by -63.33%, while revenue for the quarter reached $264.03m , beating expectations by +23.41%.
Earnings released on 25 Nov 2025
EPS came in at -$0.18 falling short of the estimated -$0.11 by -61.33%, while revenue for the quarter reached $256.47m , beating expectations by +46.29%.
Earnings released on 7 Aug 2025
EPS came in at -$1.26 falling short of the estimated -$0.94 by -34.04%, while revenue for the quarter reached $27.77m , missing expectations by -81.98%.
Earnings released on 12 May 2025
EPS came in at $2.75 surpassing the estimated -$0.06 by +4.68k%, while revenue for the quarter reached $542.71m , beating expectations by +366.77%.
Earnings released on 10 Feb 2025
EPS came in at -$1.39 falling short of the estimated -$0.42 by -230.95%, while revenue for the quarter reached $2.50m , missing expectations by -86.88%.
Earnings released on 26 Nov 2024
EPS came in at -$1.38 falling short of the estimated -$1.05 by -31.43%, while revenue for the quarter reached $3.55m , missing expectations by -93.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.38 falling short of the estimated -$0.58 by -137.93%.
Earnings released on 9 May 2024
EPS came in at -$1.02 falling short of the estimated -$0.06 by -1.60k%.
Earnings released on 6 Feb 2024
EPS came in at -$1.24 falling short of the estimated -$0.78 by -58.97%, while revenue for the quarter reached $3.55m , missing expectations by -87.97%.
Earnings released on 29 Nov 2023
EPS came in at -$1.03 falling short of the estimated -$0.70 by -47.14%, while revenue for the quarter reached $16.10m , missing expectations by -68.27%.
Earnings released on 7 Aug 2023
EPS came in at -$0.96 falling short of the estimated -$0.58 by -65.52%, while revenue for the quarter reached $15.83m , missing expectations by -73.55%.
Earnings released on 2 May 2023
EPS came in at $0.45 surpassing the estimated -$0.64 by +170.31%, while revenue for the quarter reached $146.27m , beating expectations by +221.61%.
Earnings released on 6 Feb 2023
EPS came in at -$0.39 falling short of the estimated $1.14 by -134.21%, while revenue for the quarter reached $62.55m , missing expectations by -61.51%.
Earnings released on 28 Nov 2022
EPS came in at -$0.81 falling short of the estimated -$0.57 by -42.11%, while revenue for the quarter reached $31.58m , missing expectations by -37.22%.
Earnings released on 4 Aug 2022
EPS came in at -$0.68 falling short of the estimated -$0.45 by -51.11%, while revenue for the quarter reached $32.41m , missing expectations by -29.16%.
Earnings released on 10 May 2022
EPS came in at $0.41 surpassing the estimated -$0.08 by +612.50%, while revenue for the quarter reached $151.81m , beating expectations by +24.28%.
Earnings released on 2 Feb 2022
EPS came in at -$0.60 falling short of the estimated -$0.22 by -172.73%, while revenue for the quarter reached $27.44m , missing expectations by -42.61%.
Earnings released on 22 Nov 2021
EPS came in at -$0.61 falling short of the estimated -$0.11 by -478.47%, while revenue for the quarter reached $38.28m , beating expectations by +2.83%.
Earnings released on 5 Aug 2021
EPS came in at -$0.29 falling short of the estimated -$0.08 by -262.50%, while revenue for the quarter reached $45.89m , beating expectations by +22.31%.
ARWR Stock Performance
Access detailed ARWR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
